Vol. 23/No. 7 | OncologyLive

Advances in Learning Health Care Systems Strive to Optimize Cancer Care

April 19, 2022


As technology and cancer care continue to become intertwined at every level, there is an imperative need to effectively process and use vast amounts of data to provide the highest level of care for patients.

Targeted Treatment Boom Reshapes Differentiated Thyroid Cancer Landscape

April 18, 2022

Marcia S. Brose, MD, PhD, FASCO, and a panel of thyroid cancer experts share their insights into the evolving treatment landscape, including the use of VEGF receptor inhibitors and some of the precision medicine treatments now identified for molecularly selected subsets of patients with differentiated thyroid cancer, such as BRAF, RET, and TRK inhibitors.

Treatment Optimization Efforts Seek to Overcome Resistance in Advanced CML

April 15, 2022

Elias J. Jabbour, MD, and Matthew S. Davids, MD, MMSc, review data on asciminib and ponatinib in the post–second generation TKI setting for chronic myeloid leukemia that were presented at the 2021 ASH Meeting and Exposition.

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis

April 05, 2022


Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.